Roche: USD8.3bn invested to buy InterMune

NEUTRAL, Fair Value CHF272 (+2%)

News published on August Monday 25, 2014
Share on
Roche is acquiring InterMune in an all-cash transaction for USD8.3bn and gains access to Esbriet, a new therapeutic option to treat IPF. With this deal, it strengthens its Respiratory portfolio. The deal is said to be Core EPS neutral in 2015 and accretive afterwards. It is a good use of cash in our view.

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities